Orchestra BioMed Holdings, Inc. develops biomedical technologies through strategic partnerships with global medical device companies. Its recurring news centers on two late-stage cardiovascular programs: Atrioventricular Interval Modulation Therapy, or AVIM Therapy, for hypertension, and Virtue Sirolimus AngioInfusion Balloon, or Virtue SAB, for atherosclerotic artery disease.
Company updates commonly cover pivotal trial activity, clinical and mechanistic data presentations, FDA Breakthrough Device Designation matters for AVIM Therapy, strategic financing from partners, revenue participation arrangements, and equity-based employee inducement grants. Financial-result releases also discuss cash resources, non-recurring revenue tied to program agreements, and execution of the company's partnership-driven development model.
Orchestra BioMed (OBIO) will present its Virtue Sirolimus AngioInfusion Balloon and pivotal trial design at TCT on November 1, 2026.
The presentation will review drug delivery, preclinical and clinical evidence, and the actively enrolling Virtue Trial. This randomized U.S. trial plans approximately 740 patients and compares Virtue SAB with the AGENT paclitaxel-coated balloon for coronary in-stent restenosis, or renewed narrowing within a stent. In the earlier SABRE study, the three-year target lesion failure rate was 14.3% among all treated patients, with no additional repeat procedures at the treated lesion between years one and three.
Orchestra BioMed (OBIO) will host an R&D Day on November 12, 2026, focused on AVIM Therapy and Virtue SAB. The event begins at 3:00 p.m. ET in New York City and will be webcast live.
Company leaders and cardiologists will discuss uncontrolled hypertension in patients indicated for pacemakers, restenosis in coronary stent interventions, and the therapies’ potential to address these needs. Sessions will cover the BACKBEAT and Virtue pivotal trials, the Medtronic collaboration, upcoming clinical milestones and commercial potential. A replay will be available afterward on the company’s investor website.
Orchestra BioMed (OBIO) surpassed its enrollment target for the BACKBEAT pivotal trial of Atrioventricular Interval Modulation (AVIM) Therapy, with 330 patients randomized. As of September 30, 2026, enrollment exceeded the target of 316 patients across 81 sites in 13 countries. Conducted with Medtronic, the trial evaluates AVIM Therapy in patients needing pacemakers whose hypertension remains uncontrolled despite medication.
The randomized, double-blind trial compares AVIM Therapy plus continued medication and pacing with continued medication and standard pacing alone. Primary endpoints assess blood-pressure change and device safety at three months. Orchestra BioMed and Medtronic intend to submit primary results for late-breaking presentation consideration in Q2 2027. Assuming positive results, Medtronic plans prompt marketing application submissions to the FDA and other global regulators; commercialization remains subject to regulatory approval.
Orchestra BioMed (OBIO) will feature its investigational Atrioventricular Interval Modulation (AVIM) Therapy in two sessions at HRX Live 2026, the Heart Rhythm Society’s innovation-focused meeting in Atlanta from September 18-20, 2026.
A sponsored roundtable will review AVIM Therapy’s mechanism of action, clinical evidence on blood pressure reduction and cardiac function, and provide an update on the BACKBEAT Global Pivotal Trial, as well as discuss the collaboration with Medtronic to develop and commercialize AVIM Therapy for uncontrolled hypertension in pacemaker-indicated patients. A second panel will examine the expanding role of permanent cardiac pacing beyond bradycardia, with AVIM Therapy highlighted among emerging pacing-based applications for hypertension and hypertensive heart disease.
Orchestra BioMed (OBIO) received a $6.1 million milestone payment on September 14, 2026, tied to Haemonetics’ acquisition of Vivasure Medical. This follows an approximately $5 million upfront payment in January 2026, bringing total cash proceeds from the transaction in 2026 to approximately $11 million, which completes the amount previously expected for this year.
The company remains eligible for up to approximately $10 million in additional revenue-based earnout payments, for total potential proceeds of up to $21 million. Vivasure had been a strategic holding of Orchestra BioMed since the company’s formation. Management states that monetizing this holding provides incremental capital to advance its pivotal programs, including AVIM Therapy for uncontrolled hypertension and the Virtue Sirolimus AngioInfusion Balloon for atherosclerotic artery disease.
Orchestra BioMed (OBIO) granted stock options for an aggregate 133,000 common shares to seven newly hired employees on September 1, 2026. The options were issued under the company’s 2025 New Hire Inducement Plan as a material inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). Each grant will vest over a four-year period. Orchestra BioMed states that it is disclosing these awards to comply with Nasdaq’s inducement grant disclosure requirements.
Orchestra BioMed (Nasdaq: OBIO) announced that Chairman and CEO David Hochman is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026, at 9:00 a.m. ET in New Hope, Pennsylvania. The company also plans to host one-on-one investor meetings that day.
Orchestra BioMed (Nasdaq: OBIO) announced that Chairman and CEO David Hochman will present at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026 at 1:30 p.m. ET. The company will also hold one-on-one investor meetings on September 9 and 10. A live webcast and replay will be available via Orchestra BioMed’s Investor Relations website.
Orchestra BioMed (Nasdaq: OBIO) reported second quarter 2026 results and updates on its pivotal cardiovascular programs. The BACKBEAT global pivotal trial of AVIM Therapy, conducted with Medtronic, is on track to reach 284 evaluable randomized patients by the end of Q3 2026, with primary endpoint data presentation targeted for Q2 2027. The Virtue SAB pivotal trial for coronary in-stent restenosis continues to progress with additional site activations and patient enrollment, and AVIM Therapy received a second FDA Breakthrough Device Designation.
According to Orchestra BioMed, Q2 2026 cash, cash equivalents and marketable securities totaled $110.0 million, including $35 million in new strategic capital from Medtronic and Ligand, providing projected runway into Q4 2027. Q2 revenue was $0.1 million, research and development expenses were $16.6 million (up 20% year over year), selling, general and administrative expenses were $5.8 million (down 7%), and net loss attributable to common stockholders was $24.1 million, or ($0.38) per share. The company was added to the Russell 3000 and Russell 2000 indexes and plans an R&D Day on November 12, 2026, in New York City.
Orchestra BioMed (Nasdaq: OBIO) announced that it joined the broad-market Russell 3000® Index and the small-cap Russell 2000® Index, effective after the U.S. market close on June 26, 2026.
Membership, based on FTSE Russell’s market-cap rankings and style attributes, lasts until the next semi-annual reconstitution and brings automatic inclusion in related growth and value indexes.
Russell indexes are widely used benchmarks, with approximately $12.2 trillion in assets tied to their U.S. indexes.